# EDGAR Filing Document

**Accession Number:** 0001815776
**File Stem:** 0000950170-23-008770
**Filing Date:** 2023-3
**Character Count:** 18433
**Document Hash:** a9afd12be4ecd40090f7a1a1e010d0eb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-23-008770.hdr.sgml**: 20230320

**ACCESSION NUMBER**: 0000950170-23-008770

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 5

**FILED AS OF DATE**: 20230320

**DATE AS OF CHANGE**: 20230320

**EFFECTIVENESS DATE**: 20230320

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Graphite Bio, Inc.
- **CENTRAL INDEX KEY:** 0001815776
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 844867570
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-270694
- **FILM NUMBER:** 23746591

**BUSINESS ADDRESS:**
- **STREET 1:** 201 HASKINS WAY, SUITE 210
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** (650) 484-0886

**MAIL ADDRESS:**
- **STREET 1:** 201 HASKINS WAY, SUITE 210
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Integral Medicines, Inc.
- **DATE OF NAME CHANGE:** 20200622

**As filed with the Securities and Exchange Commission on March 20, 2023**

**Registration No. 333 -** 

**UNITED STATES<br>SECURITIES AND EXCHANGE COMMISSION<br>WASHINGTON, D.C. 20549**

------

**FORM S-8**

**REGISTRATION STATEMENT**

**Under**

**The Securities Act of 1933**

------

**GRAPHITE BIO, INC.**

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | |
|:---|:---|
| **Delaware** | **84-4867570** |
| **(State or other jurisdiction of<br>incorporation or organization)** | **(I.R.S. Employer<br>Identification No.)** |
| **201 Haskins Way, Suite 210** | **201 Haskins Way, Suite 210** |
| **South San Francisco, CA 94080** | **South San Francisco, CA 94080** |
| **(650) 484-0886** | **(650) 484-0886** |
| **(Address, including zip code and telephone number, including area code, of Registrant's principal executive offices)** | **(Address, including zip code and telephone number, including area code, of Registrant's principal executive offices)** |
| **Graphite Bio, Inc. 2021 Stock Option and Incentive Plan** | **Graphite Bio, Inc. 2021 Stock Option and Incentive Plan** |
| **Graphite Bio, Inc. 2021 Employee Stock Purchase Plan** | **Graphite Bio, Inc. 2021 Employee Stock Purchase Plan** |
| **Josh Lehrer, M.D.** | **Josh Lehrer, M.D.** |
| **President and Chief Executive Officer** | **President and Chief Executive Officer** |
| **201 Haskins Way, Suite 210** | **201 Haskins Way, Suite 210** |
| **South San Francisco, CA 94080** | **South San Francisco, CA 94080** |
| **(650) 484-0886** | **(650) 484-0886** |
| **(Name, address, including zip code, and telephone number, including area code, of agent for service)** | **(Name, address, including zip code, and telephone number, including area code, of agent for service)** |

---

------

---

| | | |
|:---|:---|:---|
|  | **Copies to:** |  |
| **Mitchell S. Bloom** |  | **Josh Lehrer, M.D.** |
| **Maggie Wong** |  | **President and Chief Executive Officer** |
| **Shoaib Ghias** |  | **201 Haskins Way, Suite 210** |
| **Goodwin Procter LLP** |  | **South San Francisco, CA 94080** |
| **Three Embarcadero Center, Floor 28** |  | **(650) 484-0886** |
| **San Francisco, CA 94111** |  |  |
| **(415) 733-6000** |  |  |

---

------

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☒ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**EXPLANATORY NOTE**

This Registration Statement on Form S-8 registers 2,911,088 additional shares of Common Stock under the Graphite Bio, Inc. 2021 Stock Option and Incentive Plan (the "2021 Plan") and 564,000 additional shares of Common Stock under the Graphite Bio, Inc. 2021 Employee Stock Purchase Plan (the "2021 ESPP"). The number of shares of Common Stock reserved and available for issuance under the 2021 Plan is subject to an automatic annual increase on each January 1, beginning January 1, 2022, by an amount equal to the lesser of: (i) 5% of the number of shares of Common Stock issued and outstanding on the immediately preceding December 31, and (ii) such lesser number of shares of Common Stock as determined by the Administrator (as defined in the 2021 Plan). Accordingly, on January 1, 2023, the number of shares of Common Stock reserved and available for issuance under the 2021 Plan increased by 2,911,088. The number of shares of Common Stock reserved and available for issuance under the 2021 ESPP is subject to an automatic annual increase on each January 1, beginning January 1, 2022, by an amount equal to the least of: (i) 564,000 shares of Common Stock, (ii) 1% of the number of shares of Common Stock issued and outstanding on the immediately preceding December 31, and (iii) such lesser number of shares of Common Stock as determined by the Administrator (as defined in the 2021 ESPP). Accordingly, on January 1, 2023, the number of shares of Common Stock reserved and available for issuance under the 2021 ESPP increased by 564,000. The additional shares are of the same class as other securities relating to the 2021 Plan and the 2021 ESPP for which the Registrant's registration statements filed on Form S-8 filed with the Securities and Exchange Commission on June 28, 2021 (File No. [<u>333-257486</u>](https://www.sec.gov/Archives/edgar/data/1815776/000119312521202189/d166188ds8.htm)) (the "2021 Registration Statement") and on March 21, 2022 (File No. [<u>333-263747</u>](https://www.sec.gov/Archives/edgar/data/1815776/000119312522080574/d333905ds8.htm)) (the "2022 Registration Statement") are effective, and the contents of the 2021 Registration Statement and 2022 Registration Statement, as amended, or as modified or superseded pursuant to Rule 412 under the Securities Act of 1933, as amended (the "Securities Act"), are incorporated by reference into this Registration Statement.

**Part II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 8 Exhibits**

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit Number** | **Description** |
| 4.1 | [<u>Amended and Restated Certificate of Incorporation, as currently in effect (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K (File No. 001-40532) filed on June 30, 2021).</u>](https://www.sec.gov/Archives/edgar/data/0001815776/000119312521204869/d169897dex31.htm) |
| 4.2 | [<u>Amended and Restated Bylaws, as currently in effect (incorporated by reference to Exhibit 3.2 to the Registrant's Current Report on Form 8-K (File No. 001-40532) filed on June 30, 2021).</u>](https://www.sec.gov/Archives/edgar/data/0001815776/000119312521204869/d169897dex32.htm) |
| 4.3 | [<u>Amended and Restated Investors' Rights Agreement by and among the Registrant and certain of its stockholders, dated March 11, 2021 (incorporated by reference to Exhibit 4.2 to the Registrant's Registration Statement on Form S-1 (File No. 333-256838) filed on June 4, 2021).</u>](https://www.sec.gov/Archives/edgar/data/0001815776/000119312521183167/d132211dex42.htm) |
| 4.4 | [<u>Specimen Common Stock Certificate (incorporated by reference to Exhibit 4.1 to Amendment No. 1 to the Registrant's Registration Statement on Form S-1 (File No. 333-256838) filed on June 11, 2021).</u>](https://www.sec.gov/Archives/edgar/data/0001815776/000119312521189004/d132211dex41.htm) |
| 5.1\* | [<u>Opinion of Goodwin Procter LLP.</u>](grph-ex5_1.htm) |
| 23.1\* | [<u>Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm.</u>](grph-ex23_1.htm) |
| 23.2\* | [<u>Consent of Goodwin Procter LLP (included in Exhibit 5.1).</u>](grph-ex5_1.htm) |
| 24.1\* | [<u>Power of Attorney (included on signature page to this registration statement).</u>](#signatures) |
| 99.1 | [<u>2021 Stock Option and Incentive Plan and forms of award agreements thereunder (incorporated by reference to Exhibit 10.2 to the Registrant's Registration Statement on Form S-1, as amended (File No. 333–256838)).</u>](https://www.sec.gov/Archives/edgar/data/1815776/000119312521194083/d132211dex102.htm) |
| 99.2 | [<u>2021 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.3 to the Registrant's Registration Statement on Form S-1, as amended (File No. 333–256838)).</u>](https://www.sec.gov/Archives/edgar/data/1815776/000119312521194083/d132211dex103.htm) |
| 107\* | [<u>Filing Fee Table</u>](grph-exfiling_fees.htm) |
| \* | Filed herewith |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of South San Francisco, State of California, on this 20th day of March, 2023.

---

| | |
|:---|:---|
|  | **GRAPHITE BIO, INC.** |
| By: | /s/ Josh Lehrer |
|  | Name: Josh Lehrer, M.D. |
|  | Title: President and Chief Executive Officer |

---

**POWER OF ATTORNEY AND SIGNATURES**

KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints each of Josh Lehrer and Alethia Young as such person's true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person's name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in their capacities and on the date indicated.

---

| | | |
|:---|:---|:---|
| **NAME** | **TITLE** | **DATE** |
| /s/ Josh Lehrer | President, Director and Chief Executive Officer | March 20, 2023 |
| Josh Lehrer, M.D. | (Principal Executive Officer) |  |
| /s/ Alethia Young | Chief Financial Officer | March 20, 2023 |
| Alethia Young | (Principal Financial and Accounting Officer) |  |
| /s/ Perry Karsen | Chairman of the Board and Director | March 20, 2023 |
| Perry Karsen |  |  |
| /s/ Abraham Bassan | Director | March 20, 2023 |
| Abraham Bassan |  |  |
| /s/ Jerel Davis | Director | March 20, 2023 |
| Jerel Davis, Ph. D. |  |  |
| /s/ Kristen M. Hege | Director | March 20, 2023 |
| Kristen M. Hege, M.D. |  |  |
| /s/ Joseph Jimenez | Director | March 20, 2023 |
| Joseph Jimenez |  |  |
| /s/ Matthew Porteus | Director | March 20, 2023 |
| Matthew Porteus, M.D., Ph.D. |  |  |
| /s/ Carlo Rizzuto | Director | March 20, 2023 |
| Carlo Rizzuto, Ph.D. |  |  |
| /s/ Smital Shah | Director | March 20, 2023 |
| Smital Shah |  |  |

---

------

---

| | | |
|:---|:---|:---|
| /s/ Jo Viney | Director | March 20, 2023 |
| Jo Viney, Ph.D. |  |  |

---

------

## Ex-5

**Exhibit 5.1** 

---

| | |
|:---|:---|
| ![img188438493_0.jpg](img188438493_0.jpg)  | Goodwin Procter LLP<br>3 Embarcadero Center <br>San Francisco, CA 94111<br>goodwinlaw.com<br>+1 415 733 6000 |

---

March 20, 2023

Graphite Bio, Inc.

201 Haskins Way, Suite 210

South San Francisco, CA 94080

Re: Securities Being Registered under Registration Statement on Form S-8

We have acted as counsel to you in connection with your filing of a Registration Statement on Form S-8 (the "Registration Statement") pursuant to the Securities Act of 1933, as amended (the "Securities Act"), on or about the date hereof relating to an aggregate of 3,475,088 shares (the "Shares") of Common Stock, $0.00001 par value per share ("Common Stock"), of Graphite Bio, Inc., a Delaware corporation (the "Company"), that may be issued pursuant to the Company's 2021 Stock Option and Incentive Plan and 2021 Employee Stock Purchase Plan (collectively, the "Plans").

We have reviewed such documents and made such examination of law as we have deemed appropriate to give the opinions set forth below. We have relied, without independent verification, on certificates of public officials and, as to matters of fact material to the opinion set forth below, on certificates of officers of the Company.

The opinion set forth below is limited to the Delaware General Corporation Law.

For purposes of the opinion set forth below, we have assumed that no event occurs that causes the number of authorized shares of Common Stock available for issuance by the Company to be less than the number of then unissued Shares.

Based on the foregoing, we are of the opinion that the Shares have been duly authorized and, upon issuance and delivery against payment therefor in accordance with the terms of the Plans, will be validly issued, fully paid and nonassessable.

This opinion letter and the opinion it contains shall be interpreted in accordance with the Core Opinion Principles as published in 74 Business Lawyer 815 (Summer 2019).

We hereby consent to the inclusion of this opinion as Exhibit 5.1 to the Registration Statement. In giving our consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations thereunder.

---

| |
|:---|
| Very truly yours, |
| /s/ Goodwin Procter LLP |
| GOODWIN PROCTER LLP |

---

ACTIVE/122050291.4

------

## Ex-23

**Exhibit 23.1**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the incorporation by reference in this Registration Statement on Form S-8 of our report dated March 20, 2023 relating to the financial statements of Graphite Bio, Inc. appearing in the Annual Report on Form 10-K of Graphite Bio, Inc. for the year ended December 31, 2022.

/s/ Deloitte & Touche LLP

San Francisco, California

March 20, 2023

------

## Ex-Filing

**Exhibit 107**

**Calculation of Filing Fee Tables**

**Form S-8**

(Form Type)

**Graphite Bio, Inc.**

(Exact Name of Registrant as Specified in its Charter)

<u>Table 1: Newly Registered Securities</u>

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Security Type** | **Security Class Title** | **Fee Calculation Rule** | **Amount Registered(1)** | **Proposed Maximum Offering Price Per Share(2)** | **Maximum Aggregate Offering Price** | **Fee Rate** | **Amount of Registration Fee** |
| &nbsp;&nbsp;Equity | Common Stock, $0.00001 par value per share | Rule 457(c) and Rule 457(h)(1) | 2911088(3) | $2.42 | $7044833 | 0.0001102 | $776.34 <br>|
| &nbsp;&nbsp;Equity | Common Stock, $0.00001 par value per share | Rule 457(c) and Rule 457(h)(1) | 564000(4) | $2.42 | $1364880 | 0.0001102 | $150.41 |
| **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** |  |  |  | $926.75<br>|
| **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** |  |  |  | $0 |
| **Net Fee Due** | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** |  |  |  | $926.75 |

---

(1) Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional shares of common stock which become issuable under the above-named plans by reason of any stock dividend, stock split, recapitalization or any other similar transaction effected without the receipt of consideration which results in an increase in the number of our outstanding shares of common stock. Pursuant to Rule 416(c) under the Securities Act, this Registration Statement shall also cover an indeterminate amount of interests to be offered or sold pursuant to the employee benefit plans described herein.

(2) Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) and (h)(1) of the Securities Act, and based on $2.42 , the average of the high and low sale prices of the of the Registrant's common stock as reported on the Nasdaq Global Market on March 15, 2023.

(3) Represents an automatic increase to the number of shares available for issuance under the Registrant's 2021 Stock Option and Incentive Plan (the "2021 Plan") effective as of January 1, 2023. Shares available for issuance under the 2021 Plan were previously registered on Form S-8 filed with the Securities and Exchange Commission on June 28, 2021 (File No. [<u>333-</u> <u>257486</u>](https://www.sec.gov/Archives/edgar/data/1815776/000119312521202189/d166188ds8.htm)) and on March 21, 2022 (File No. [<u>333-263747</u>](https://www.sec.gov/Archives/edgar/data/1815776/000119312522080574/d333905ds8.htm)).

(4) Represents an automatic increase to the number of shares available for issuance under the Registrant's 2021 Employee Stock Purchase Plan (the "2021 ESPP") effective as of January 1, 2023. Shares available for issuance under the 2021 ESPP were previously registered on Form S-8 filed with the Securities and Exchange Commission on June 28, 2021 (File No. [<u>333- 257486</u>](https://www.sec.gov/Archives/edgar/data/1815776/000119312521202189/d166188ds8.htm)) and on March 21, 2022 (File No. [<u>333-263747</u>](https://www.sec.gov/Archives/edgar/data/1815776/000119312522080574/d333905ds8.htm)).

ACTIVE/122051278.2

------